Veloxis Pharmaceuticals, Inc. (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Veloxis Pharmaceuticals, Inc.

Let's transform transplant medicine. Together

Founded 2002

Cary, United States 126 employees Post Ipo Debt Total: $60.00M Biotechnology, Health Care +1

Veloxis Pharmaceuticals, Inc. is a specialty pharmaceutical company that is dedicated to enhancing the lives of transplant patients. Operating as a subsidiary of Asahi Kasei, the company is headquartered in Cary, North Carolina, USA and focuses on the global development and commercialization of medications for transplant patients and those with related serious diseases. Founded in 2002, Veloxis Pharmaceuticals is deeply committed to innovating and addressing the challenges faced by transplant patients, aiming to improve their overall experience. The company's dedication to the transplant community is exemplified in its slogan, "Let's transform transplant medicine. Together," and its profound understanding of the significance of organ transplants in patients' lives. An important milestone in the company's growth trajectory was the $60.00M Post-IPO Debt investment on 14 February 2018, led by Athyrium Capital Management, which signified a critical point in its expansion and strategic development. As the company continues to make advancements in the Biotechnology, Health Care, and Pharmaceutical industries, it remains dedicated to its mission of improving the transplant journey for patients globally. Interested readers can access Veloxis Pharmaceuticals' Community Guidelines via this link: https://bit.ly/3FQr7Wg.

Funding Stage	Amount	Investors	Lead Investors	Date
Post-IPO Debt	••••••	1		14 Feb 2018

Funding Stage

Amount

Investors

Lead Investors

Date

Post-IPO Debt

••••••

14 Feb 2018

FAQ About Veloxis Pharmaceuticals, Inc.

Let's transform transplant medicine. Together

Veloxis Pharmaceuticals, Inc. was founded in 2002.

Veloxis Pharmaceuticals, Inc. is headquartered in Cary, United States.

Veloxis Pharmaceuticals, Inc. operates in the following industries: Biotechnology, Health Care, Pharmaceutical.

Veloxis Pharmaceuticals, Inc. has approximately 126 employees.

Veloxis Pharmaceuticals, Inc. has completed 1 funding round, raising a total of $60.00M. The latest funding stage is Post Ipo Debt.

Top alternatives and competitors to Veloxis Pharmaceuticals, Inc. include BioNova Pharmaceuticals (Shanghai) Limited, Zevra Therapeutics, Magenta Therapeutics, CareDx, Inc., BMT InfoNet. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Veloxis Pharmaceuticals, Inc. and BioNova Pharmaceuticals (Shanghai) Limited are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Veloxis Pharmaceuticals, Inc.

General Information

Track Veloxis Pharmaceuticals, Inc.

Discover More

About Veloxis Pharmaceuticals, Inc.

Funding Rounds & Investors (1)

Veloxis Pharmaceuticals, Inc. Alternatives & Competitors

FAQ About Veloxis Pharmaceuticals, Inc.

Don't just browse. Track.